Name | MipoMersen sodiuM |
---|---|
Synonyms |
Kynamro
mipomersen |
Description | Mipomersen (sodium) is a second-generation 20-base phosphorothioate ASO targeted to human apoB-100[1][2]. |
---|---|
Related Catalog | |
In Vitro | Mipomersen predominantly distributes to the liver and decreases the production of apoB-100, the primary structural protein of the atherogenic lipoproteins including low density lipoprotein (LDL), thereby reducing plasma LDL-cholesterol and apoB-100 concentrations[2]. Apolipoprotein (apo) B, a large amphipathic protein, plays a fundamental role in human lipoprotein metabolism. ApoB-100 is also a ligand for LDL receptor-mediated endocytosis of LDL by cells[2]. |
References |
[1]. Philip Hair, et al. Mipomersen sodium: first global approval. Drugs. 2013 Apr;73(5):487-93. |
Molecular Formula | C230H305N67Na19O122P19S19 |
---|